Pharmaceutical - Anti-Arthritics/Rheumatics

Filter

Popular Filters

1 to 25 of 220 results

New Ph III data to support filing for AbbVie’s Humira in HS

13-10-2014

US pharma company AbbVie has reported new data with its mega blockbuster arthritis drug Humira (adalimumab)…

AbbVieAnti-Arthritics/RheumaticsDermatologicalsHumiraPharmaceuticalResearch

AbbVie gains expanded approval for Humira by FDA

AbbVie gains expanded approval for Humira by FDA

06-10-2014

US drugmaker AbbVie has received approval from the US Food and Drug Administration for an extension of…

AbbVieAnti-Arthritics/RheumaticsHumiraPharmaceuticalRegulationUSA

Lilly to drop Ph III tabalumab trial in lupus due to poor efficacy

Lilly to drop Ph III tabalumab trial in lupus due to poor efficacy

02-10-2014

US pharma major Eli Lilly has said it will discontinue development of tabalumab, which is being studied…

Anti-Arthritics/RheumaticsEli LillyImmunologicalsPharmaceuticalResearchtabalumabUSA

Novartis' secukinumab meets primary and secondary endpoints in Phase III psoriatic arthritis trials

Novartis' secukinumab meets primary and secondary endpoints in Phase III psoriatic arthritis trials

25-09-2014

Swiss drug major Novartis' AIN457 (secukinumab) has met the primary and key secondary endpoints in two…

Anti-Arthritics/RheumaticsDermatologicalsNovartisPharmaceuticalResearchsecukinumabSwitzerland

Opportunity for emerging agents in Crohn’s disease, report finds

Opportunity for emerging agents in Crohn’s disease, report finds

18-09-2014

New research from Decision Resources Group has found that only a small proportion of patients with Crohn's…

Anti-Arthritics/RheumaticsBiosimilarsEntyvioHumiraPharmaceuticalRemicadeResearchStelaraUSAXeljanz

Rheumatoid arthritis drug market will grow to $18.2 billion in 2023, report

17-09-2014

The rheumatoid arthritis (RA) disease-modifying antirheumatic drug market will increase from $14 billion…

Anti-Arthritics/RheumaticsbaricitinibBiosimilarsEli LillyEuropeIncyteJapanMarkets & MarketingPfizerPharmaceuticalUSAVertexXeljanz

Merck’s odanacatib succeeds in Ph III osteoporosis trial

Merck’s odanacatib succeeds in Ph III osteoporosis trial

16-09-2014

US pharma giant Merck & Co has announced positive data from the pivotal Phase III fracture outcomes study…

Anti-Arthritics/RheumaticsMerck & CoodanacatibPharmaceuticalResearchWomen's Health

Positive new data for AbbVie’s Humira in HS

Positive new data for AbbVie’s Humira in HS

11-09-2014

US pharma group AbbVie has released results from a Phase III pivotal study demonstrating that its blockbuster…

AbbVieAnti-Arthritics/RheumaticsDermatologicalsHumiraPharmaceuticalResearch

Roche’s RoActemra gains EU approval for use in early RA

Roche’s RoActemra gains EU approval for use in early RA

08-09-2014

The European Commission has approved Swiss pharma major Roche’s RoActemra (tocilizumab) for use in…

ActemraAnti-Arthritics/RheumaticsEuropeInterleukin 6PharmaceuticalRegulationRoActemraRoche

Novo Nordisk pulls out of inflammatory disorders research

Novo Nordisk pulls out of inflammatory disorders research

02-09-2014

Danish diabetes care giant Novo Nordisk says it has decided to discontinue all its R&D activities within…

Anti-Arthritics/RheumaticsInflammatory diseasesNovo NordiskPharmaceutical

Ablynx out-licenses ozoralizumab for Greater China to Eddingpharm

Ablynx out-licenses ozoralizumab for Greater China to Eddingpharm

01-09-2014

Belgian drug developer Ablynx has expanded its relationship with China’s Eddingpharm, by granting the…

AblynxAnti-Arthritics/RheumaticsChinaEddingpharmLicensingMarkets & MarketingozoralizumabPharmaceutical

Scottish Medicines Consortium approves Roche's subcutaneous RoActemra for NHS use

Scottish Medicines Consortium approves Roche's subcutaneous RoActemra for NHS use

11-08-2014

The Scottish Medicines Consortium has approved the prescribing on the National Health Service of Roche’s…

Anti-Arthritics/RheumaticsImmunologyImmunosuppressantsNHSPharmaceuticalRegulationRoActemraRocheTocilizumabUK

Pfizer granted European approval for Enbrel in early-stage inflammatory joint disease

Pfizer granted European approval for Enbrel in early-stage inflammatory joint disease

06-08-2014

US pharma giant Pfizer has been granted a license extension by the European Commission for Enbrel (etanercept)…

Anti-Arthritics/RheumaticsArthritisChronic, lifelong inflammatory diseaseEnbrelPfizerPharmaceuticalRegulationSpondyloarthropathyUSA

US PhRMA firms developing nearly 100 new medicines for arthritis

US PhRMA firms developing nearly 100 new medicines for arthritis

28-07-2014

The USA’s biopharmaceutical research companies are developing 92 innovative new medicines to help the…

AnatomyAnti-Arthritics/RheumaticsBiopharmaceutical researchHealthHealth Medical PharmaMedicinePharmaceuticalResearchUSA

Medac’s Rasuvo approved for RA while Antares’ injunction is denied

Medac’s Rasuvo approved for RA while Antares’ injunction is denied

14-07-2014

USA-based Medac Pharma, a wholly-owned subsidiary of privately-held German firm medac GmbH, says that…

Antares PharmaAnti-Arthritics/RheumaticsLegalMedac PharmaPharmaceuticalRasuvoRegulationUSA

Astellas details pipeline progress at R&D meeting

Astellas details pipeline progress at R&D meeting

11-07-2014

Japanese drug major Astellas Pharmaceuticals outlined its research framework at its R&D meeting held…

Anti-Arthritics/RheumaticsAntibiotics and Infectious diseasesAstellas PharmaBetmigaisavuconazoleJapanNephrology and HepatologyOncologyPharmaceuticalroxadustatXtandi

Mariel Therapeutics to acquire Stryker's BMP-7 assets

Mariel Therapeutics to acquire Stryker's BMP-7 assets

08-07-2014

US clinical-stage drug developer Mariel Therapeutics has entered into a definitive agreement to acquire…

Anti-Arthritics/RheumaticsMariel TherapeuticsMergers & AcquisitionsNephrology and HepatologyPharmaceuticalStryker Corp

Fidia completes establishment of operations in North America

Fidia completes establishment of operations in North America

08-07-2014

Fidia Pharma USA, a wholly-owned subsidiary of privately-held Italian drugmaker Fidia Farmaceutici, says…

Anti-Arthritics/RheumaticsFidia FarmaceuticiManagementMarkets & MarketingPharmaceuticalUSA

Positive association between adherence and anti-TNF therapy compared to conventional therapy

Positive association between adherence and anti-TNF therapy compared to conventional therapy

11-06-2014

US drugmaker AbbVie has released results from its multi-country ALIGN study, which shows that across…

AbbVieAnti-Arthritics/RheumaticsHealthcareInflammatory diseasesPharmaceutical

Pfizer’s tofacitinib meets primary endpoints in Ph III psoriasis study

26-05-2014

US pharma giant Pfizer on Friday announced positive results from the Oral treatment Psoriasis Trial (OPT)…

Anti-Arthritics/RheumaticsDermatologicalsPfizerPharmaceuticalResearchtofacitinib

New treatment funded for severe gout in New Zealand

21-05-2014

Patients with severe gout will soon have a new treatment option as New Zealand’s Pharmaceutical Management…

AdenuricAnti-Arthritics/RheumaticsfebuxostatFinancialMenariniNew ZealandPharmaceuticalRegulation

Positive top-line results for MedImmune RA and lupus treatments

Positive top-line results for MedImmune RA and lupus treatments

13-05-2014

Anglo-Swedish drug major AstraZeneca has announced that two key molecules in its global biologics R&D…

Anti-Arthritics/RheumaticsAstraZenecaBahija JallalHealthHealth Medical PharmaMajorMedicineMedImmunePharmaceuticalResearchUK

Roche gains EU approval for new RoActemra formulation

Roche gains EU approval for new RoActemra formulation

28-04-2014

Swiss drug major Roche revealed this morning that the subcutaneous formulation of RoActemra (tocilizumab)…

Anti-Arthritics/RheumaticsEuropePharmaceuticalRegulationRoActemraRoche

1 to 25 of 220 results

Parexel

Parexel

Back to top